Trials / Completed
CompletedNCT06688292
The Safety and Effectiveness of Taneasy and Actein in COPD Patients
A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Actein Effervescent Tablets 600MG in COPD Subjects
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Bun Yao Biotechnology Co., Ltd · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of Taneasy 600mg granules and Actein effervescent tablets 600MG administered twice daily for 14 days in treatment of COPD Disease.
Detailed description
The study will enroll 40\~60 patients and complete 40 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Taneasy 600mg granules | Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis. |
| DRUG | Actein effervescent 600mg | Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, pulmonary emphysema, mucoviscidosis and bronchiectasis. |
Timeline
- Start date
- 2024-09-20
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2024-11-14
- Last updated
- 2025-02-05
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT06688292. Inclusion in this directory is not an endorsement.